JP2005535574A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005535574A5 JP2005535574A5 JP2003584048A JP2003584048A JP2005535574A5 JP 2005535574 A5 JP2005535574 A5 JP 2005535574A5 JP 2003584048 A JP2003584048 A JP 2003584048A JP 2003584048 A JP2003584048 A JP 2003584048A JP 2005535574 A5 JP2005535574 A5 JP 2005535574A5
- Authority
- JP
- Japan
- Prior art keywords
- aliphatic
- compound
- ring
- aryl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 113
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 41
- 125000001424 substituent group Chemical group 0.000 claims 38
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 36
- 229910052757 nitrogen Inorganic materials 0.000 claims 36
- 229910052760 oxygen Inorganic materials 0.000 claims 35
- 229910052717 sulfur Inorganic materials 0.000 claims 34
- 125000005842 heteroatoms Chemical group 0.000 claims 32
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims 31
- 125000003118 aryl group Chemical group 0.000 claims 24
- 125000000623 heterocyclic group Chemical group 0.000 claims 24
- -1 1,2-methylenedioxy Chemical group 0.000 claims 18
- 125000001072 heteroaryl group Chemical group 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 239000001257 hydrogen Substances 0.000 claims 18
- 125000001931 aliphatic group Chemical group 0.000 claims 17
- 125000006717 (C3-C10) cycloalkenyl group Chemical group 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 15
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 14
- 125000004429 atoms Chemical group 0.000 claims 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 14
- 125000004122 cyclic group Chemical group 0.000 claims 12
- 125000002619 bicyclic group Chemical group 0.000 claims 11
- 229910052736 halogen Inorganic materials 0.000 claims 11
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 10
- 230000002401 inhibitory effect Effects 0.000 claims 9
- 150000002829 nitrogen Chemical group 0.000 claims 9
- 125000005843 halogen group Chemical group 0.000 claims 8
- 239000003112 inhibitor Substances 0.000 claims 8
- 125000002950 monocyclic group Chemical group 0.000 claims 7
- 229920000728 polyester Polymers 0.000 claims 7
- 201000002674 obstructive nephropathy Diseases 0.000 claims 6
- 125000004043 oxo group Chemical group O=* 0.000 claims 6
- 125000000165 tricyclic carbocycle group Chemical group 0.000 claims 6
- 125000006721 (C5-C10) heteroaryl (C1-C6) alkyl group Chemical group 0.000 claims 5
- 125000006719 (C6-C10) aryl (C1-C6) alkyl group Chemical group 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 102000033147 ERVK-25 Human genes 0.000 claims 4
- 108091005771 Peptidases Proteins 0.000 claims 4
- 239000004365 Protease Substances 0.000 claims 4
- 239000003443 antiviral agent Substances 0.000 claims 4
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims 4
- 229910052796 boron Inorganic materials 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000004432 carbon atoms Chemical group C* 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000006574 non-aromatic ring group Chemical group 0.000 claims 4
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 4
- 125000000464 thioxo group Chemical group S=* 0.000 claims 4
- 210000001124 Body Fluids Anatomy 0.000 claims 3
- 102000012479 Serine Proteases Human genes 0.000 claims 3
- 108010022999 Serine Proteases Proteins 0.000 claims 3
- IQFYYKKMVGJFEH-CSMHCCOUSA-N Telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 3
- 229960005311 telbivudine Drugs 0.000 claims 3
- 101710036216 ATEG_03556 Proteins 0.000 claims 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N Amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 2
- 229960003805 Amantadine Drugs 0.000 claims 2
- 210000004369 Blood Anatomy 0.000 claims 2
- 102000003996 Interferon beta Human genes 0.000 claims 2
- 108090000467 Interferon beta Proteins 0.000 claims 2
- 102000005741 Metalloproteases Human genes 0.000 claims 2
- 108010006035 Metalloproteases Proteins 0.000 claims 2
- 101710003000 ORF1/ORF2 Proteins 0.000 claims 2
- 101700030467 Pol Proteins 0.000 claims 2
- 102000007501 Thymosin Human genes 0.000 claims 2
- 108010046075 Thymosin Proteins 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 230000002519 immonomodulatory Effects 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 230000002584 immunomodulator Effects 0.000 claims 2
- 229940121354 immunomodulators Drugs 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 101710004466 rgy Proteins 0.000 claims 2
- 101710030364 rgy1 Proteins 0.000 claims 2
- 101710030359 rgy2 Proteins 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 241000790917 Dioxys <bee> Species 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000240 adjuvant Effects 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 238000011109 contamination Methods 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229940044627 gamma-interferon Drugs 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrugs Drugs 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000011232 storage material Substances 0.000 claims 1
- 210000001519 tissues Anatomy 0.000 claims 1
- 0 CC(*)C(C)C1CCCC1 Chemical compound CC(*)C(C)C1CCCC1 0.000 description 17
- GDBCVIHZQYAWLU-UHFFFAOYSA-N CC(C(CCC1CC23N(C)CCC2)N1C3=O)=O Chemical compound CC(C(CCC1CC23N(C)CCC2)N1C3=O)=O GDBCVIHZQYAWLU-UHFFFAOYSA-N 0.000 description 1
- VTOITISQJGMVSQ-UHFFFAOYSA-N CC(C(CCC1CCCC2NC)N1C2=O)=O Chemical compound CC(C(CCC1CCCC2NC)N1C2=O)=O VTOITISQJGMVSQ-UHFFFAOYSA-N 0.000 description 1
- TUFWJBPCWWPJJX-UHFFFAOYSA-N CC(C(CCC1NCC2NC)N1C2=O)=O Chemical compound CC(C(CCC1NCC2NC)N1C2=O)=O TUFWJBPCWWPJJX-UHFFFAOYSA-N 0.000 description 1
- HJNGFPBZCZRPJX-UHFFFAOYSA-N CC(C(CCC1NCCC2NC)N1C2=O)=O Chemical compound CC(C(CCC1NCCC2NC)N1C2=O)=O HJNGFPBZCZRPJX-UHFFFAOYSA-N 0.000 description 1
- JCIZAGNGBHWOES-UHFFFAOYSA-N CC(C(CCC1SCC2NC)N1C2=O)=O Chemical compound CC(C(CCC1SCC2NC)N1C2=O)=O JCIZAGNGBHWOES-UHFFFAOYSA-N 0.000 description 1
- RECBQSVGWIRVQV-UHFFFAOYSA-N CC(C(CCC1SCCC2NC)N1C2=O)=O Chemical compound CC(C(CCC1SCCC2NC)N1C2=O)=O RECBQSVGWIRVQV-UHFFFAOYSA-N 0.000 description 1
- QFXDFUFPSSTROV-UHFFFAOYSA-N CC(C(CCCC1CC23N(C)CCC2)N1C3=O)=O Chemical compound CC(C(CCCC1CC23N(C)CCC2)N1C3=O)=O QFXDFUFPSSTROV-UHFFFAOYSA-N 0.000 description 1
- ZXJCQACFSYGMPO-UHFFFAOYSA-N CC(C(CCSC1CC23N(C)CCC2)N1C3=[U])=O Chemical compound CC(C(CCSC1CC23N(C)CCC2)N1C3=[U])=O ZXJCQACFSYGMPO-UHFFFAOYSA-N 0.000 description 1
- RXSWFHPGDPYGRL-IDKOKCKLSA-N CC(C(CC[C@@H]1CCC2NC)N1C2=O)=O Chemical compound CC(C(CC[C@@H]1CCC2NC)N1C2=O)=O RXSWFHPGDPYGRL-IDKOKCKLSA-N 0.000 description 1
- NQIMYAPMJDMGFM-UHFFFAOYSA-N CC(C(CSC1CC23N(C)CCC2)N1C3=O)=O Chemical compound CC(C(CSC1CC23N(C)CCC2)N1C3=O)=O NQIMYAPMJDMGFM-UHFFFAOYSA-N 0.000 description 1
- DVGMAZIZBADOBU-UHFFFAOYSA-N CC(C)(CC(C)=O)CNC Chemical compound CC(C)(CC(C)=O)CNC DVGMAZIZBADOBU-UHFFFAOYSA-N 0.000 description 1
- XQIUXEOBOCSGFV-UHFFFAOYSA-N CC1=CC=CCC1C[Sc](C)C Chemical compound CC1=CC=CCC1C[Sc](C)C XQIUXEOBOCSGFV-UHFFFAOYSA-N 0.000 description 1
- QVVPJFZQUZTCKD-UHFFFAOYSA-O CCC(C)C(C(C(NC(C)CC)=N)=O)NC(C(C)(CC1C2CCCC1)N2C(C(C)(C(C)(C)C)NC(C(C1CCCCC1)NC(C([NH3+])=CC=N)=O)=O)=O)=O Chemical compound CCC(C)C(C(C(NC(C)CC)=N)=O)NC(C(C)(CC1C2CCCC1)N2C(C(C)(C(C)(C)C)NC(C(C1CCCCC1)NC(C([NH3+])=CC=N)=O)=O)=O)=O QVVPJFZQUZTCKD-UHFFFAOYSA-O 0.000 description 1
- SUNIXXUMZRROKD-OWDBQKORSA-N CCC(C1)[C@]1(C(C(NC1C=C1)=O)=O)NC([C@](C1)(C1C(CCC1)C2C1C(C)(C)[C@@H]1NC([C@H](C3CCCCC3)NC(c3nccnc3)=O)=O)N2C1=O)=O Chemical compound CCC(C1)[C@]1(C(C(NC1C=C1)=O)=O)NC([C@](C1)(C1C(CCC1)C2C1C(C)(C)[C@@H]1NC([C@H](C3CCCCC3)NC(c3nccnc3)=O)=O)N2C1=O)=O SUNIXXUMZRROKD-OWDBQKORSA-N 0.000 description 1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37184602P | 2002-04-11 | 2002-04-11 | |
PCT/US2003/011459 WO2003087092A2 (en) | 2002-04-11 | 2003-04-11 | Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009128587A Division JP2009185081A (ja) | 2002-04-11 | 2009-05-28 | セリンプロテアーゼ、特にhcvns3−ns4aプロテアーゼのインヒビター |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005535574A JP2005535574A (ja) | 2005-11-24 |
JP2005535574A5 true JP2005535574A5 (US08039623-20111018-C00020.png) | 2006-06-01 |
Family
ID=29250748
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003584048A Pending JP2005535574A (ja) | 2002-04-11 | 2003-04-11 | セリンプロテアーゼ、特にhcvns3−ns4aプロテアーゼのインヒビター |
JP2009128587A Pending JP2009185081A (ja) | 2002-04-11 | 2009-05-28 | セリンプロテアーゼ、特にhcvns3−ns4aプロテアーゼのインヒビター |
JP2010151000A Pending JP2010241821A (ja) | 2002-04-11 | 2010-07-01 | セリンプロテアーゼ、特にhcvns3−ns4aプロテアーゼのインヒビター |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009128587A Pending JP2009185081A (ja) | 2002-04-11 | 2009-05-28 | セリンプロテアーゼ、特にhcvns3−ns4aプロテアーゼのインヒビター |
JP2010151000A Pending JP2010241821A (ja) | 2002-04-11 | 2010-07-01 | セリンプロテアーゼ、特にhcvns3−ns4aプロテアーゼのインヒビター |
Country Status (18)
Families Citing this family (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL194025B1 (pl) * | 1996-10-18 | 2007-04-30 | Vertex Pharma | Inhibitory proteaz serynowych, a zwłaszcza proteazy wirusa NS3 zapalenia wątroby C, kompozycja farmaceutyczna i zastosowanie inhibitorów proteaz serynowych |
AU2001251165A1 (en) * | 2000-04-03 | 2001-10-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
AU2002348414B2 (en) * | 2001-10-24 | 2009-10-01 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine protease, particularly hepatitis C virus NS3-NS4A protease, incorporating a fused ring system |
SG159385A1 (en) * | 2002-04-11 | 2010-03-30 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease |
CN100453553C (zh) | 2003-04-11 | 2009-01-21 | 沃泰克斯药物股份有限公司 | 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂 |
AU2011203054B2 (en) * | 2003-04-11 | 2012-04-26 | Vertex Pharmaceuticals, Incorporated | Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease |
TW200510391A (en) * | 2003-04-11 | 2005-03-16 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
EP1646642A2 (en) * | 2003-07-18 | 2006-04-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
MY148123A (en) * | 2003-09-05 | 2013-02-28 | Vertex Pharma | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
JP4685775B2 (ja) | 2003-09-18 | 2011-05-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | セリンプロテアーゼ、とりわけhcvns3−ns4aプロテアーゼの阻害剤 |
NZ546663A (en) | 2003-10-10 | 2010-01-29 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
US8187874B2 (en) | 2003-10-27 | 2012-05-29 | Vertex Pharmaceuticals Incorporated | Drug discovery method |
EP1944042A1 (en) | 2003-10-27 | 2008-07-16 | Vertex Pharmceuticals Incorporated | Combinations for HCV treatment |
JP4942485B2 (ja) | 2003-10-28 | 2012-05-30 | バーテックス ファーマシューティカルズ インコーポレイテッド | Fischer−fink型合成および続くアシル化による4,5−ジアルキル−3−アシル−ピロール−2−カルボン酸誘導体の製造 |
CA2552319C (en) | 2004-01-30 | 2012-08-21 | Medivir Ab | Hcv ns-3 serine protease inhibitors |
EP1711515A2 (en) * | 2004-02-04 | 2006-10-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
NZ554351A (en) * | 2004-10-01 | 2010-02-26 | Vertex Pharma | HCV NS3-NS4A protease inhibition using VX-950, also known as telaprevir |
US20060189559A1 (en) | 2004-12-20 | 2006-08-24 | Ruilin Zhao | Method and system for treating hepatitis C |
JP5021625B2 (ja) * | 2005-04-20 | 2012-09-12 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 患者モニタリングシステム |
CN101218224B (zh) | 2005-05-13 | 2013-05-08 | Viro化学制药公司 | 治疗或预防黄病毒感染的组合物和方法 |
EP2305695A3 (en) | 2005-07-25 | 2011-07-27 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
PE20070343A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Inhibidores macrociclicos del virus de la hepatitis c |
PE20070210A1 (es) | 2005-07-29 | 2007-04-16 | Tibotec Pharm Ltd | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
JP5426164B2 (ja) | 2005-07-29 | 2014-02-26 | ヤンセン・アールアンドデイ・アイルランド | C型肝炎ウイルスの大環式インヒビター |
PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
JO2768B1 (en) * | 2005-07-29 | 2014-03-15 | تيبوتيك فارماسيوتيكالز ليمتد | Large cyclic inhibitors of hepatitis C virus |
AU2006274862B2 (en) | 2005-07-29 | 2012-03-22 | Medivir Ab | Macrocyclic inhibitors of hepatitis C virus |
MY139988A (en) * | 2005-07-29 | 2009-11-30 | Tibotec Pharm Ltd | Macrocylic inhibitors of hepatitis c virus |
AU2006274861B2 (en) | 2005-07-29 | 2012-11-08 | Medivir Ab | Macrocyclic inhibitors of hepatitis C virus |
EP1913015B1 (en) | 2005-07-29 | 2013-12-11 | Janssen R&D Ireland | Macrocyclic inhibitors of hepatitis c virus |
ES2373685T3 (es) | 2005-07-29 | 2012-02-07 | Tibotec Pharmaceuticals | Inhibidores macrocíclicos del virus de la hepatitis c. |
JP2009505966A (ja) * | 2005-08-02 | 2009-02-12 | バーテックス ファーマシューティカルズ インコーポレイテッド | セリンプロテアーゼのインヒビター |
US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
CN101415705B (zh) * | 2005-10-11 | 2011-10-26 | 因特蒙公司 | 抑制丙型肝炎病毒复制的化合物和方法 |
EP1951748B1 (en) | 2005-11-11 | 2013-07-24 | Vertex Pharmaceuticals, Inc. | Hepatitis c virus variants |
US7705138B2 (en) | 2005-11-11 | 2010-04-27 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
EP1991229A2 (en) * | 2006-02-27 | 2008-11-19 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
CA2646229A1 (en) | 2006-03-16 | 2007-09-27 | Vertex Pharmaceuticals Incorporated | Deuterated hepatitis c protease inhibitors |
KR101059593B1 (ko) * | 2006-04-11 | 2011-08-25 | 노파르티스 아게 | Hcv/hiv 억제제 및 이들의 용도 |
WO2007120595A2 (en) * | 2006-04-11 | 2007-10-25 | Novartis Ag | Amines for the treatment of hcv |
UA100669C2 (ru) * | 2006-06-01 | 2013-01-25 | Санофі-Авентіс | Спироциклические нитрилы как ингибиторы протеазы, способ их получения (варианты) и лекарственное средство на их основе |
RU2008152171A (ru) * | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
JP5290186B2 (ja) | 2006-11-15 | 2013-09-18 | ヴァイロケム ファーマ インコーポレイテッド | フラビウイルス感染症の治療または予防用のチオフェン類似体 |
TWI406660B (zh) | 2006-11-17 | 2013-09-01 | Tibotec Pharm Ltd | C型肝炎病毒之巨環抑制劑 |
AP2009004960A0 (en) * | 2007-02-27 | 2009-08-31 | Vertex Pharma | Co-crystals and pharmaceutical compositions comprising the same |
CA2679426A1 (en) * | 2007-02-27 | 2008-09-04 | Luc Farmer | Inhibitors of serine proteases |
US20090155209A1 (en) * | 2007-05-03 | 2009-06-18 | Blatt Lawrence M | Novel macrocyclic inhibitors of hepatitis c virus replication |
EP2185524A1 (en) * | 2007-05-10 | 2010-05-19 | Intermune, Inc. | Novel peptide inhibitors of hepatitis c virus replication |
EP2436682A1 (en) * | 2007-08-30 | 2012-04-04 | Vertex Pharmceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
MX2010006736A (es) | 2007-12-21 | 2010-10-15 | Avila Therapeutics Inc | Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos. |
MX2010006738A (es) | 2007-12-21 | 2010-10-15 | Avila Therapeutics Inc | Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos. |
US8309685B2 (en) | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
MX2010011306A (es) * | 2008-04-15 | 2010-11-09 | Intermune Inc | Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c. |
US8188137B2 (en) | 2008-08-15 | 2012-05-29 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
AP2011005695A0 (en) * | 2008-10-15 | 2011-06-30 | Intermune Inc | Therapeutic antiviral poptides. |
TW201036612A (en) | 2008-12-22 | 2010-10-16 | Gilead Sciences Inc | Antiviral compounds |
AR075584A1 (es) * | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
WO2010138791A1 (en) | 2009-05-29 | 2010-12-02 | Schering Corporation | Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c |
AU2009352688B2 (en) | 2009-09-15 | 2014-04-17 | Taigen Biotechnology Co., Ltd. | HCV protease inhibitors |
MX2012003500A (es) * | 2009-09-28 | 2012-08-01 | Intermune Inc | Nuevos inhibidores macrocíclicos de la replicación de virus de la hepatitis c. |
EP2504329A1 (en) | 2009-11-25 | 2012-10-03 | Vertex Pharmaceuticals Incorporated | 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections |
WO2011066241A1 (en) | 2009-11-25 | 2011-06-03 | Schering Corporation | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
US20130156731A1 (en) | 2009-12-22 | 2013-06-20 | Kevin X. Chen | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas |
MX2012007420A (es) | 2009-12-24 | 2012-07-23 | Vertex Pharma | Analogos para el tratamiento o prevencion de infecciones de flavivirus. |
ES2558554T3 (es) | 2010-03-09 | 2016-02-05 | Merck Sharp & Dohme Corp. | Compuestos de sililo tricíclicos condensados y métodos de uso de los mismos para el tratamiento de enfermedades víricas |
WO2011119860A1 (en) | 2010-03-24 | 2011-09-29 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
WO2011119858A1 (en) | 2010-03-24 | 2011-09-29 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
AU2011232331A1 (en) | 2010-03-24 | 2012-10-11 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of Flavivirus infections |
CA2794181A1 (en) | 2010-03-24 | 2011-09-29 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
WO2011156545A1 (en) | 2010-06-09 | 2011-12-15 | Vertex Pharmaceuticals Incorporated | Viral dynamic model for hcv combination therapy |
US20130157258A1 (en) | 2010-06-15 | 2013-06-20 | Vertex Pharmaceuticals Incorporated | Hcv ns5b protease mutants |
CA2803248A1 (en) | 2010-06-28 | 2012-01-12 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flavivirus infections |
JP2013531011A (ja) | 2010-06-28 | 2013-08-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | フラビウイルス感染の処置または予防のための化合物および方法 |
WO2012006070A1 (en) | 2010-06-28 | 2012-01-12 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flavivirus infections |
WO2012018534A2 (en) | 2010-07-26 | 2012-02-09 | Schering Corporation | Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases |
JP2013534249A (ja) | 2010-08-17 | 2013-09-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | フラビウイルス科ウイルス感染の処置または予防のための化合物および方法 |
EP2621279B1 (en) | 2010-09-29 | 2018-04-04 | Merck Sharp & Dohme Corp. | Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases |
WO2012142075A1 (en) | 2011-04-13 | 2012-10-18 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
EA201391519A1 (ru) | 2011-04-13 | 2014-03-31 | Мерк Шарп И Доум Корп. | 2'-замещенные нуклеозидные производные и способы их применения для лечения вирусных заболеваний |
WO2013016499A1 (en) | 2011-07-26 | 2013-01-31 | Vertex Pharmaceuticals Incorporated | Methods for preparation of thiophene compounds |
AU2012286853A1 (en) | 2011-07-26 | 2013-05-02 | Vertex Pharmaceuticals Incorporated | Thiophene compounds |
WO2013033901A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases |
WO2013033899A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases |
WO2013033900A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases |
WO2013039876A1 (en) | 2011-09-14 | 2013-03-21 | Merck Sharp & Dohme Corp. | Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases |
US20130123276A1 (en) | 2011-11-14 | 2013-05-16 | Sven Ruf | Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases |
NZ630805A (en) | 2012-03-22 | 2016-01-29 | Alios Biopharma Inc | Pharmaceutical combinations comprising a thionucleotide analog |
WO2014053533A1 (en) | 2012-10-05 | 2014-04-10 | Sanofi | Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation |
WO2014134251A1 (en) | 2013-02-28 | 2014-09-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions |
US10167298B2 (en) | 2013-10-30 | 2019-01-01 | Merck Sharp & Dohme Corp. | Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof |
EP2899207A1 (en) | 2014-01-28 | 2015-07-29 | Amikana.Biologics | New method for testing HCV protease inhibition |
MA52119A (fr) | 2015-10-19 | 2018-08-29 | Ncyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
SG11201804152RA (en) | 2015-11-19 | 2018-06-28 | Incyte Corp | Heterocyclic compounds as immunomodulators |
ES2844374T3 (es) | 2015-12-22 | 2021-07-22 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
EP3452476B1 (en) | 2016-05-06 | 2021-12-15 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
TW201808902A (zh) | 2016-05-26 | 2018-03-16 | 美商英塞特公司 | 作為免疫調節劑之雜環化合物 |
ES2927984T3 (es) | 2016-06-20 | 2022-11-14 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
US10526315B2 (en) | 2016-06-21 | 2020-01-07 | Orion Ophthalmology LLC | Carbocyclic prolinamide derivatives |
EA201990069A1 (ru) | 2016-06-21 | 2019-06-28 | ОРИОН ОФТАЛМОЛОДЖИ ЭлЭлСи | Производные гетероциклического пролинамида |
ES2930092T3 (es) | 2016-07-14 | 2022-12-07 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
ES2941716T3 (es) | 2016-08-29 | 2023-05-25 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
EP3558985B1 (en) | 2016-12-22 | 2022-09-07 | Incyte Corporation | Benzooxazole derivatives as immunomodulators |
ES2874756T3 (es) | 2016-12-22 | 2021-11-05 | Incyte Corp | Derivados de triazolo[1,5-A]piridina como inmunomoduladores |
US20180179179A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
RU2650610C1 (ru) | 2017-02-28 | 2018-04-16 | Васильевич Иващенко Александр | Противовирусная композиция и способ ее применения |
MX2020010321A (es) | 2018-03-30 | 2021-01-08 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores. |
DK3790877T3 (da) | 2018-05-11 | 2023-04-24 | Incyte Corp | Tetrahydro-imidazo[4,5-c]pyridinderivater som pd-l1-immunmodulatorer |
US20220227806A1 (en) * | 2019-06-07 | 2022-07-21 | University Of Massachusetts | Hepatitis c virus ns3/4a protease inhibitors |
EP4010342A1 (en) | 2019-08-09 | 2022-06-15 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
CA3155852A1 (en) | 2019-09-30 | 2021-04-08 | Incyte Corporation | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS AS IMMUNOMODULATORS |
MX2022005651A (es) | 2019-11-11 | 2022-07-27 | Incyte Corp | Sales y formas cristalinas de un inhibidor de la proteina de muerte celular programada 1 (pd-1)/ligando de muerte celular programada 1 (pd-l1). |
JP2023548859A (ja) | 2020-11-06 | 2023-11-21 | インサイト・コーポレイション | Pd-1/pd-l1阻害剤ならびにその塩及び結晶形態を作製するためのプロセス |
WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
WO2022099075A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Crystalline form of a pd-1/pd-l1 inhibitor |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
EP0907659A1 (en) | 1996-05-10 | 1999-04-14 | Schering Corporation | Synthetic inhibitors of hepatitis c virus ns3 protease |
US5990276A (en) | 1996-05-10 | 1999-11-23 | Schering Corporation | Synthetic inhibitors of hepatitis C virus NS3 protease |
PL194025B1 (pl) * | 1996-10-18 | 2007-04-30 | Vertex Pharma | Inhibitory proteaz serynowych, a zwłaszcza proteazy wirusa NS3 zapalenia wątroby C, kompozycja farmaceutyczna i zastosowanie inhibitorów proteaz serynowych |
GB9623908D0 (en) * | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
GB9707659D0 (en) | 1997-04-16 | 1997-06-04 | Peptide Therapeutics Ltd | Hepatitis C NS3 Protease inhibitors |
DE69827956T2 (de) | 1997-08-11 | 2005-04-14 | Boehringer Ingelheim (Canada) Ltd., Laval | Peptidanaloga mit inhibitorischer wirkung auf hepatitis c |
CA2294049A1 (en) | 1997-08-11 | 1999-02-18 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptides |
AU1416099A (en) * | 1997-11-28 | 1999-06-16 | Schering Corporation | Single-chain recombinant complexes of hepatitis c virus ns3 protease and ns4a cofactor peptide |
US6075150A (en) * | 1998-01-26 | 2000-06-13 | Cv Therapeutics, Inc. | α-ketoamide inhibitors of 20S proteasome |
IT1299134B1 (it) | 1998-02-02 | 2000-02-29 | Angeletti P Ist Richerche Bio | Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi |
AU3376699A (en) | 1998-03-31 | 1999-10-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
GB9812523D0 (en) | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
AR022061A1 (es) | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos. |
US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
DE19836514A1 (de) | 1998-08-12 | 2000-02-17 | Univ Stuttgart | Modifikation von Engineeringpolymeren mit N-basischen Gruppe und mit Ionenaustauschergruppen in der Seitenkette |
GB9825946D0 (en) | 1998-11-26 | 1999-01-20 | Angeletti P Ist Richerche Bio | Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease |
UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
US7122627B2 (en) * | 1999-07-26 | 2006-10-17 | Bristol-Myers Squibb Company | Lactam inhibitors of Hepatitis C virus NS3 protease |
AU6371900A (en) | 1999-07-26 | 2001-02-13 | Du Pont Pharmaceuticals Company | Lactam inhibitors of hepatitis c virus ns3 protease |
WO2001016300A2 (en) * | 1999-08-31 | 2001-03-08 | Basf Aktiengesellschaft | Method of identifying inhibitors of cdc25 |
JP2003526634A (ja) * | 1999-12-03 | 2003-09-09 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | C型肝炎ウイルスNS3プロテアーゼのα−ケトアミド阻害剤 |
WO2001064678A2 (en) | 2000-02-29 | 2001-09-07 | Bristol-Myers Squibb Pharma Company | Inhibitors of hepatitis c virus ns3 protease |
AU2001251165A1 (en) * | 2000-04-03 | 2001-10-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
WO2001077113A2 (en) | 2000-04-05 | 2001-10-18 | Schering Corporation | Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties |
PL358591A1 (en) | 2000-04-19 | 2004-08-09 | Schering Corporation | Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising alkyl and aryl alanine p2 moieties |
MXPA03000626A (es) | 2000-07-21 | 2004-07-30 | Schering Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c. |
AR029851A1 (es) | 2000-07-21 | 2003-07-16 | Dendreon Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c |
EP1301527A2 (en) | 2000-07-21 | 2003-04-16 | Corvas International, Inc. | Peptides as ns3-serine protease inhibitors of hepatitis c virus |
CN102372764A (zh) | 2000-07-21 | 2012-03-14 | 先灵公司 | 用作丙型肝炎病毒ns3-丝氨酸蛋白酶抑制剂的新型肽 |
AR034127A1 (es) * | 2000-07-21 | 2004-02-04 | Schering Corp | Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento |
SV2003000617A (es) * | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
AU2001282132A1 (en) * | 2000-09-12 | 2002-03-26 | Degussa A.G. | Isolation and sequencing of the pknb gene of c. glutamicum |
US6846806B2 (en) | 2000-10-23 | 2005-01-25 | Bristol-Myers Squibb Company | Peptide inhibitors of Hepatitis C virus NS3 protein |
BR0115447A (pt) | 2000-11-20 | 2005-10-18 | Bristol Myers Squibb Co | Inibidores de tripeptìdeo de hepatite c |
WO2002048116A2 (en) | 2000-12-13 | 2002-06-20 | Bristol-Myers Squibb Pharma Company | Inhibitors of hepatitis c virus ns3 protease |
WO2002048157A2 (en) | 2000-12-13 | 2002-06-20 | Bristol-Myers Squibb Pharma Company | Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors |
GB0107924D0 (en) | 2001-03-29 | 2001-05-23 | Angeletti P Ist Richerche Bio | Inhibitor of hepatitis C virus NS3 protease |
JP4455056B2 (ja) | 2001-07-11 | 2010-04-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | 架橋二環式セリンプロテアーゼ阻害剤 |
AU2002348414B2 (en) * | 2001-10-24 | 2009-10-01 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine protease, particularly hepatitis C virus NS3-NS4A protease, incorporating a fused ring system |
SG159385A1 (en) * | 2002-04-11 | 2010-03-30 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease |
CN100453553C (zh) * | 2003-04-11 | 2009-01-21 | 沃泰克斯药物股份有限公司 | 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂 |
TW200510391A (en) * | 2003-04-11 | 2005-03-16 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
EP1646642A2 (en) * | 2003-07-18 | 2006-04-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
EP1711515A2 (en) * | 2004-02-04 | 2006-10-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
-
2003
- 2003-04-11 SG SG200700139-9A patent/SG159385A1/en unknown
- 2003-04-11 JP JP2003584048A patent/JP2005535574A/ja active Pending
- 2003-04-11 KR KR1020117004808A patent/KR20110028665A/ko not_active Application Discontinuation
- 2003-04-11 CN CNB03809665XA patent/CN100381440C/zh not_active Expired - Fee Related
- 2003-04-11 CA CA2481369A patent/CA2481369C/en not_active Expired - Fee Related
- 2003-04-11 EP EP12160782A patent/EP2468744A2/en not_active Withdrawn
- 2003-04-11 NZ NZ561851A patent/NZ561851A/en not_active IP Right Cessation
- 2003-04-11 RU RU2004133044/04A patent/RU2004133044A/ru not_active Application Discontinuation
- 2003-04-11 US US10/412,600 patent/US7273885B2/en not_active Expired - Fee Related
- 2003-04-11 CN CNA2008100823499A patent/CN101245097A/zh active Pending
- 2003-04-11 TW TW092108412A patent/TW200403236A/zh unknown
- 2003-04-11 AU AU2003223602A patent/AU2003223602B8/en not_active Ceased
- 2003-04-11 PL PL03373399A patent/PL373399A1/xx not_active Application Discontinuation
- 2003-04-11 MX MXPA04009938A patent/MXPA04009938A/es active IP Right Grant
- 2003-04-11 EP EP03719741A patent/EP1497282A2/en not_active Withdrawn
- 2003-04-11 KR KR10-2004-7016168A patent/KR20040099425A/ko not_active Application Discontinuation
- 2003-04-11 WO PCT/US2003/011459 patent/WO2003087092A2/en active Application Filing
- 2003-04-11 NZ NZ575692A patent/NZ575692A/en not_active IP Right Cessation
-
2004
- 2004-10-10 IL IL16445504A patent/IL164455A0/xx unknown
- 2004-10-12 ZA ZA200408243A patent/ZA200408243B/en unknown
- 2004-11-10 NO NO20044889A patent/NO20044889L/no unknown
-
2006
- 2006-01-27 HK HK06101291A patent/HK1081196A1/xx not_active IP Right Cessation
-
2007
- 2007-07-23 US US11/880,629 patent/US20070292933A1/en not_active Abandoned
-
2009
- 2009-05-28 JP JP2009128587A patent/JP2009185081A/ja active Pending
- 2009-06-03 US US12/477,581 patent/US20100173851A1/en not_active Abandoned
- 2009-10-30 AU AU2009233604A patent/AU2009233604A1/en not_active Abandoned
-
2010
- 2010-07-01 JP JP2010151000A patent/JP2010241821A/ja active Pending
-
2011
- 2011-05-26 NO NO20110773A patent/NO20110773L/no unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005535574A5 (US08039623-20111018-C00020.png) | ||
JP2007532474A5 (US08039623-20111018-C00020.png) | ||
CA2481369A1 (en) | Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease | |
RU2006105002A (ru) | Ингибиторы сериновых протеаз, в частности, нс-3-нс4а протеазы | |
WO2005035525B1 (en) | 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
RU2006115558A (ru) | Ингибиторы сериновых протеаз, особенно hcv ns3-ns4a протеазы | |
CA2536436A1 (en) | 2-amido-4-aryloxy-1-carbonyl pyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
CN101443350B (zh) | 作为抗病剂的大环化合物 | |
RU2008108024A (ru) | Ингибиторы серинпротеазы | |
RU2468029C2 (ru) | Ингибиторы hcv ns3 протеазы | |
JP2007504251A5 (US08039623-20111018-C00020.png) | ||
RU2007119390A (ru) | Соединения 4-метоксиметил-пирролидин-2-карбоновой кислоты и их производные - ингибиторы вируса гепатита с | |
AR045769A1 (es) | Inhibidores de las serina proteasas, particularmente, la proteasa ns3-ns4a del vhc (virus hepatitis c) | |
HUP0302526A2 (hu) | Makrolid vegyületek, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
IL159087A0 (en) | Bridged bicyclic compounds and pharmaceutical compositions containing the same | |
JP2009529544A5 (US08039623-20111018-C00020.png) | ||
WO2013074386A2 (en) | Hcv ns3 protease inhibitors | |
SA03240006B1 (ar) | مركب مثبط لالتهاب الكبد c | |
RU2006125377A (ru) | Гетероциклические ингибиторы аспартилпротеазы | |
CN103889439A (zh) | Hcv蛋白酶抑制剂的晶体形式 | |
RU2006109004A (ru) | 7-аминоалкилиденилгетероциклические хинолоны и нафтиридоны | |
KR20080017334A (ko) | 항바이러스 화합물 | |
CN104936949A (zh) | 用于治疗丙型肝炎的squaric衍生物 | |
CA2006263A1 (en) | Sulfated tannins and their salts | |
WO2014022636A1 (en) | Broad spectrum inhibitors of the post proline cleaving enzymes for treatment of hepatitis c virus infections |